Topics

Rna Modification System Mechanisms And Targeted Disease Therapy

DNA Metabolism And Repair Cell Programmed Death Chronic Inflammation Cancer Immunotherapy

RNA modification systems, or epitranscriptomics, add dynamic chemical marks to coding and noncoding RNA and regulate RNA fate beyond genome sequence. More than 100 RNA modifications have been identified, and m6A, m5C, pseudouridine, inosine, m1A, and hm5C are mapped across mRNA, tRNA, rRNA, snRNA, lncRNA, and other RNA classes. This field now connects RNA chemistry with gene expression, development, immunity, cancer, cardiovascular disease, neurological disease, diabetes, infection, and precision therapy[1][2].

Mechanistically, m6A is installed, removed, and interpreted by writers, erasers, and readers. METTL3 and METTL14 act as writers, ALKBH5 and FTO act as erasers, and reader proteins determine transcript fate. m6A regulates splicing, stability, translation, intracellular localization, nuclear export, RNA decay, apoptosis, autophagy, senescence, DNA damage response, immune response, and viral replication. Programmable dCas13b-m6A reader tools show that YTHDF2 can induce target transcript decay and YTHDF1 can enhance translation, demonstrating transcript-specific control of RNA output[3][4][5][6].

Disease applications now include breast cancer, leukemia, cardiovascular disease, atherosclerosis, ischemic brain injury, diabetic microvascular complications, COVID-19, depression-related plasticity, and antiviral biology. In breast cancer, m6A readers, writers, and erasers are associated with altered RNA regulation and prognosis, while m6A, A-to-I editing, and m5C in lncRNAs and miRNAs influence breast cancer development and progression. In diabetic microvascular complications, m6A modification of coding and noncoding RNAs affects diabetic cardiomyopathy, nephropathy, retinopathy, neuropathy, and dermatosis. In cardiovascular inflammation and atherosclerosis, RNA modifications regulate inflammatory signaling, lipid metabolism, vascular cell adaptation, RNA stability, alternative splicing, and microRNA biology[4][7][8][9][10].

Targeted therapy is moving from pathway association toward RNA-modifier drugs, RNA-editing biomarkers, and transcript-level intervention. Leukemia studies support RNA modifications and modifier enzymes as disease-progression indicators and therapeutic targets, while infection studies show m5C, m6A, and pseudouridine signatures in immune response, viral defense, inflammation, stress, viral entry, and immune activation. Major gaps remain in detecting RNA modifications in complex tissues, proving causality, selecting patients, and avoiding unintended transcriptome-wide effects. Future therapy should integrate direct RNA sequencing, single-transcript tools, multi-omics, modifier-enzyme targeting, and disease-specific biomarkers so RNA modification systems can become precise, reversible, and clinically actionable disease therapies[5][9][10][11][12].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-A0004 Decitabine
Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell Apoptosis. Decitabine has potent anticancer activity.
DNA Methyltransferase   Apoptosis   Nucleoside Antimetabolite/Analog  
Pancreatic Cancer   Viral Infection   Digestive System Inflammation   Urogenital Cancer   Non-Small Cell Lung Cancer   Acute Myeloid Leukemia   SARS-CoV-2 Infection   Rheumatoid Arthritis  
183
HY-10586 5-Azacytidine
5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes. 5-Azacytidine induces cell autophagy.
Organoid   Nucleoside Antimetabolite/Analog   DNA Methyltransferase   Bacterial   Autophagy   Antibiotic  
Lung Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Bacterial Infection   SARS-CoV-2 Infection   Rheumatoid Arthritis  
142
HY-L005 Epigenetics Compound Library
Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases. MCE provide a unique collection of 2,031 epigenetics-related compounds that can be used in the research of the related diseases.

Signaling Pathway Targeting Libraries

102
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-L048 Antifungal Compound Library
The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. Additionally, identifying novel drug targets is challenging because there are many similarities between fungal and human cells. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Nonetheless, fungi have developed resistance mechanisms, such as overexpression of efflux pump proteins, overexpression and changes in drug targets and biofilm formation, emphasizing the importance of discovering new antifungal drugs and therapies. Due to the limited antifungal arsenal, researchers have sought to improve treatment via different approaches, such as the combination of antifungal drugs, development of new formulations for antifungal agents and modifications to the chemical structures of traditional antifungals, etc. MCE offers a unique collection of 585 compounds with validated antifungal activities. MCE antifungal compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.

Disease Focused Libraries

87
HY-L077 Anti-Pancreatic Cancer Compound Library
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 4,336 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Disease Focused Libraries

85
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L080 Targeted Therapy Drug Library
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases. MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

Disease Focused Libraries

84
HY-L151 PROTAC Library
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy. MCE supplies a unique collection of 544 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

Compound Characteristic Classified Libraries

84
HY-L005M Epigenetics Compound Library Mini
Epigenetics involves heritable phenotypic changes that occur without alterations to the underlying DNA sequence. Key mechanisms include DNA methylation, histone modifications, and regulation by small non-coding RNAs such as microRNAs. By modifying DNA, histones, or RNA—while leaving their primary sequences intact—these processes influence molecular function and regulation, thereby playing critical roles in cellular differentiation, embryonic development, gene expression control, aging, and diseases such as cancer. MCE provide a unique collection of 295 epigenetics-related compounds. For each regulatory target and its subtype, 3 to 5 highly specific representative compounds have been retained, which can be used in epigenetic and related disease research.

Signaling Pathway Targeting Libraries

83
HY-L074 Anti-Breast Cancer Compound Library
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Disease Focused Libraries

83
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L244 High-Efficiency Gene Editing Compound Library
In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies. To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 761 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.

Signaling Pathway Targeting Libraries

83
HY-L248 RNA Binding Bioactive Compound Library
The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development. The MCE RNA-targeted bioactive compound library contains 858 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.

Signaling Pathway Targeting Libraries

83
HY-112288 C188-9
C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia.
STAT   Apoptosis   DNA Methyltransferase  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation   Obesity  
37
HY-111558 Bobcat339
Bobcat339 is a potent and selective cytosine-based inhibitor of TET enzyme, with IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription.
DNA Methyltransferase   TET Protein  
Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
29
HY-135146 GSK-3484862
GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma.
DNA Methyltransferase   Apoptosis  
Lung Cancer   Breast Cancer   Leukemia/Lymphoma/Myeloma  
26
HY-13962 SGI-1027
SGI-1027 is a DNA methyltransferase (DNMT) inhibitor, with IC50s of 7.5 μM, 8 μM, and 12.5 μM for DNMT3B, DNMT3A, and DNMT1 with poly(dI-dC) as substrate.
DNA Methyltransferase   Apoptosis  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   Rheumatoid Arthritis  
20
HY-19528 SAH
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
20
HY-13642 RG108
RG108 (N-Phthalyl-L-tryptophan) is a non-nucleoside DNA methyltransferases (DNMTs) inhibitor (IC50=115 nM) that blocks the DNMTs active site. RG108 (N-Phthalyl-L-tryptophan) causes demethylation and reactivation of tumor suppressor genes, but it does not affect the methylation of centromeric satellite sequences.
DNA Methyltransferase  
Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
15
HY-139664 GSK-3685032
GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition.
DNA Methyltransferase  
Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
15
HY-13765 6-Thioguanine
6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC50s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.
SARS-CoV   Deubiquitinase   DNA Methyltransferase   Autophagy   Apoptosis   Endogenous Metabolite  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection   Rheumatoid Arthritis  
14
HY-117275 Meclofenamic acid
Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
Fat Mass and Obesity-associated Protein (FTO)   Potassium Channel   Gap Junction Protein  
Inflammation or Immune System Disease   Alzheimer's Disease  
9
HY-B1320 Meclofenamic acid sodium
Meclofenamic acid (Meclofenamate) sodium is a non-steroidal anti-inflammatory agent (NSAID). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat - and obesity-related enzyme (FTO). Meclofenamic acid sodium has anti-inflammatory and antitumor activities.
Gap Junction Protein   Fat Mass and Obesity-associated Protein (FTO)  
Non-Small Cell Lung Cancer  
9
HY-N0086 N6-Methyladenosine
N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.

Source: Eukarya

Influenza Virus   Endogenous Metabolite  
Viral Infection  
8
HY-154919 DC-Y13-27
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (KD: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer.
YTHDF   FOXO   MMP   Pyroptosis   Interleukin Related  
Metabolic or Endocrine Disease   Breast Cancer   Colorectal Cancer   Pancreatic Cancer   Depression   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
7
HY-113137 N2,N2-Dimethylguanosine
N2,N2-Dimethylguanosine is a methylated modified nucleoside present in RNA and serves as a structural modification component of tRNA. N2,N2-Dimethylguanosine inhibits reverse transcriptase-mediated cDNA synthesis and is one of the key modifications affecting sequencing efficiency in high-throughput RNA sequencing. N2,N2-Dimethylguanosine can be selectively demethylated at one methyl group by AlkB mutant enzymes (such as D135S/L118V) and converted to N2-methylguanosine, thereby reducing the inhibition of reverse transcription.
Endogenous Metabolite  
Cancer  
4
HY-N6769 Radicicol
Radicicol is an inhibitor of Hsp90 with an IC50 value < 1 μM, and leads to proteasomal degradation. Radicicol exhibits inhibition on PDK with IC50s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB. Radicicol is also an inhibitor of fat mass and obesity-associated protein (FTO), with an IC50 value of 16.04 μM.

Source: Penicillium meleagrinum

HSP   Bacterial   Antibiotic   Parasite  
Infection  
4
HY-113081 1-Methyladenosine
1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
Endogenous Metabolite   PPAR   Hedgehog  
Pancreatic Cancer   Digestive System Inflammation   Obesity  
4
HY-P1291A PKI 14-22 amide,myristoylated TFA
PKI 14-22 amide, myristoylated TFA is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated TFA makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated TFA can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated TFA can prevent the development of analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated TFA can be used in research fields such as opioid tolerance mechanisms and antiviral drugs.
PKA   Epigenetic Reader Domain   Flavivirus  
Infection   Neurological, Eye or Ear Disease  
3
HY-P1291 PKI 14-22 amide,myristoylated
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs.
PKA   Flavivirus   Epigenetic Reader Domain  
Infection   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pain   Obesity  
3
HY-I0626 Cytosine
Cytosine is one of the four main bases found in DNA and RNA. Cytosine modifications exhibit circadian oscillations that are involved in epigenetic diversity and aging. Cytosine can be used in cancer research.
Endogenous Metabolite  
Cancer   SARS-CoV-2 Infection  
3
HY-P99575 Tarlatamab
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

Species: Human

Notch  
Inflammation or Immune System Disease   Respiratory Disease   Small Cell Lung Cancer  
3
HY-117275A Meclofenamic acid sodium hydrate
Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
Fat Mass and Obesity-associated Protein (FTO)   Potassium Channel   Gap Junction Protein   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
2
HY-RS15939 YTHDF3 Human Pre-designed siRNA Set A

YTHDF3 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Small Interfering RNA (siRNA)   YTHDF  
2
HY-B0459 Scopine
Scopine is a metabolite of Scopolamine (HY-N0296) and brain-targeting compound. Scopine significantly increases the brain exposure of Chlorambucil (HY-13593) and enhances its anti-glioma activity. Scopine can be used in targeted therapy research for brain gliomas.
Drug Metabolite  
Cancer   Neurological, Eye or Ear Disease  
2
HY-N0086R N6-Methyladenosine (Standard)
N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion. N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits.
Endogenous Metabolite   Reference Standards   Influenza Virus  
Infection  
2
HY-113011 Maltotriose
Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
Endogenous Metabolite  
2
HY-N0353 Curdione
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression.
Ferroptosis   Apoptosis   Reactive Oxygen Species (ROS)   Autophagy   Glutathione Peroxidase   Keap1-Nrf2   Heme Oxygenase (HO)   TGF-β Receptor   Indoleamine 2,3-Dioxygenase (IDO)  
Colorectal Cancer   Pancreatic Cancer   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Lung Fibrosis  
2
HY-W008091 5-Methylcytosine
5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma.

Source: prokaryotes and eukaryotes

DNA/RNA Synthesis   Endogenous Metabolite  
Colorectal Cancer   Liver Cancer  
2
HY-158301 MY-1B
MY-1B is a covalent inhibitor of the RNA Methyltransferase NSUN2 (IC50: 1.3 μM). MY-1B stereoselectively ligands active-site cysteine residues (C271) of NSUN2. MY-1B can stereoselectively and covalently bind to PSME1, disrupting the proteasome regulatory complex and downregulating the presentation of specific MHC-I subtypes.
DNA Methyltransferase   Ligands for E3 Ligase   RNA MTase  
Prostate Cancer  
2
HY-141567 Pseudouridine 5'-triphosphate
Pseudouridine 5'-triphosphate (Pseudo-UTP) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate can be used for the research of vaccinia virus infection.
DNA/RNA Synthesis  
Viral Infection  
1
HY-RS15937 YTHDF1 Human Pre-designed siRNA Set A

YTHDF1 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Small Interfering RNA (siRNA)   YTHDF  
1
HY-RS15938 YTHDF2 Human Pre-designed siRNA Set A

YTHDF2 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Small Interfering RNA (siRNA)   YTHDF  
1
HY-P10387A RSM3 TFA
RSM3 TFA is a METTL3-METTL14 complex inhibitor with a Kd of 3.10 μM for the METTL3-METTL14 complex. RSM3 TFA reduces the m6A modification level of SLC31A1 and the global RNA methylation level. RSM3 TFA upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 TFA is applicable to the research of preeclampsia and cancer.
METTL3   Apoptosis  
Cancer  
1
HY-13912G IWP-2 (GMP)
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation.
Wnt  
Cancer  
1
HY-P10387 RSM3
RSM3 is a METTL3-METTL14 complex inhibitor with a Kd of 3.10 μM for the METTL3-METTL14 complex. RSM3 reduces the m6A modification level of SLC31A1 and the global RNA methylation level. RSM3 upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 is applicable to the research of preeclampsia and cancer.
METTL3   Apoptosis   MDM-2/p53   NF-κB   Caspase  
Cancer  
1
HY-113138 3-Methyluridine
3-Methyluridine (m3U; N3-Methyluridine) is a methylated nucleotide present in ribosomal RNA (rRNA), mainly targeting specific base sites of RNA molecules such as 23S rRNA. 3-Methyluridine can introduce a methyl group at the N3 position of uracil, affecting the secondary structure stability and base pairing ability of RNA, and regulating ribosome function. For example, it affects ribosomal subunit binding and tRNA interaction. 3-Methyluridine is often used as a key raw material for the synthesis of modified nucleotides, and is used to construct RNA oligonucleotides containing methylation modifications to study the effects of RNA methylation on gene expression and drug resistance.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
1
HY-141567A Pseudouridine 5'-triphosphate trisodium solution (100 mM)
Pseudouridine 5'-triphosphate (Pseudo-UTP) trisodium solution (100 mM) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate trisodium solution (100 mM) enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate trisodium solution (100 mM) can be used for the research of vaccinia virus infection.
DNA/RNA Synthesis  
Viral Infection  
1
HY-W011209 N6-Isopentenyladenosine
N6-Isopentenyladenosine (Riboprine), an RNA modification found in cytokinins, which regulate plant growth/differentiation, and a subset of tRNAs, where it improves the efficiency and accuracy of translation. N6-Isopentenyladenosine, an end product of the mevalonate pathway, is an autophagy inhibitor with an interesting anti-melanoma activity.
Autophagy   Endogenous Metabolite  
Leukemia/Lymphoma/Myeloma  
1
HY-P99144A Anti-Mouse PD-1 Antibody (S-5001)
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.

Species: Mouse

PD-1/PD-L1  
Cancer Immunology   Immunotherapy for Melanoma   Squamous Cell Carcinoma  
1
HY-113061 Pseudouridine
Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia..
Endogenous Metabolite   Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis  
Lung Cancer   Leukemia/Lymphoma/Myeloma  
1
HY-P80223 METTL3 Antibody (YA294)
METTL3 Antibody (YA294) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to METTL3.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

1
HY-P83709 m6A Antibody (YA3446)
m6A Antibody (YA3446) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to m6A.

Host: Rabbit; Reactivity: Species independent

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

1
HY-50751G Linifanib (GMP)
Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells.
VEGFR   PDGFR  
/
HY-10407G SU 5402 (GMP)
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.
VEGFR   EGFR   PDGFR  
Cancer  
/
HY-100966S BD-1008-d5 dihydrobromide
BD-1008-d5 dihydrobromide is the deuterium labeled BD-1008 dihydrobromide (HY-100966). BD-1008 dihydrobromide is a nonselective σ receptor antagonist with Kis against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 dihydrobromide has an extremely low affinity for the D2 receptor (Ki = 1112 nM) and dopamine transporter (DAT) (Ki > 10,000 nM). BD-1008 dihydrobromide significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 dihydrobromide blocks the self-administration behavior of σ agonists.BD-1008 dihydrobromide can be used for the study of addiction therapy that target the σ receptor.
Isotope-Labeled Compounds   Sigma Receptor  
Neurological, Eye or Ear Disease  
/
HY-117275S Meclofenamic acid-d4
Meclofenamic acid-d4 is the deuterium labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker.
Isotope-Labeled Compounds   Gap Junction Protein   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-N10340 Clausine E
Clausine E, is a alkaloid which can be isolated from Clausena excavata, is a inhibitor of fat mass and obesity-associated protein (FTO) demethylase. Clausine E shows inhibitory activities against proliferation of synoviocytes and cancer cells.
Others  
/
HY-N0353R Curdione (Standard)
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression.
Reference Standards   Ferroptosis   Apoptosis   Reactive Oxygen Species (ROS)   Autophagy   Glutathione Peroxidase   Keap1-Nrf2   Heme Oxygenase (HO)   TGF-β Receptor   Indoleamine 2,3-Dioxygenase (IDO)  
Cancer  
/
HY-10227G Bortezomib (GMP)
Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
Proteasome   NF-κB   Apoptosis   Autophagy   TREM receptor  
Cancer  
/
HY-W768571 Pseudouridine-13C,15N2
Pseudouridine-13C,15N2 is the 13C- and 15N-labeled Pseudouridine (HY-113061). Pseudouridine is an isomer of uridine and the most abundant modified nucleoside in non-coding RNA. It fine-tunes and stabilizes regional structures in rRNA and tRNA, maintaining their functions in mRNA decoding, ribosome assembly, processing, and translation. Pseudouridine-modified tRNA fragments can inhibit aberrant protein synthesis and hold promise for research on myelodysplastic syndrome (MDS)-related leukemia..
Isotope-Labeled Compounds   Endogenous Metabolite   DNA/RNA Synthesis   Nucleoside Antimetabolite/Analog  
Cancer  
/
HY-W583868S 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE-d62
1-Palmitoyl-2-oleoyl-sn-glycero-3-PE-d62 (1,2-POPE-d62) is the deuterium labeled 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE (1,2-POPE; 16:0-18:1 PE) is a phosphatidylethanolamine (PE) lipid. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can induce lipid bilayer to form a hexagonal phase (HII) structure in an acidic environment and promote membrane fusion. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can enhance the endosomal escape ability of lipid nanoparticles (LNPs) and improve the cellular delivery efficiency of nucleic acid drugs such as mRNA. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can be used for LNP carrier targeting of gene therapy and mRNA vaccines.
Isotope-Labeled Compounds  
/
HY-P991270 MT204
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-W042357S Ac-rC Phosphoramidite-15N
Ac-rC Phosphoramidite-15N is 15N labeled Ac-rC Phosphoramidite (HY-W042357). Ac-rC Phosphoramidite is used for the oligoribonucleotide phosphorodithioate modification (PS2-RNA).
Isotope-Labeled Compounds   DNA/RNA Synthesis  
/
HY-113061S Pseudouridine-O18
Pseudouridine-18O is the 18O labeled Pseudouridine (HY-113061). Pseudouridine is an isomer of the nucleoside uridine, and the most abundant modified nucleoside in non-coding RNAs. Pseudouridine in rRNA and tRNA can fine-tune and stabilize the regional structure and help maintain their functions in mRNA decoding, ribosome assembly, processing and translation.
Isotope-Labeled Compounds   Endogenous Metabolite   Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis  
/
HY-P991210 Efzimfotase alfa
Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP). Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP). Efzimfotase alfa is promising for research of hypophosphatasia (HPP).
Phosphatase  
Blood or Cardio-cerebrovascular Disease  
/
HY-P4091A LSD acetate
LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics.
Biochemical Assay Reagents  
Cancer  
/
HY-P10989 NG2 binding peptide
NG2 binding peptide is a short peptide that specifically recognizes NG2 proteoglycan and can be obtained by phage screening technology. NG2 binding peptide interacts with NG2 binding sites to achieve precise targeting of tumor angiogenesis in vitro and in vivo. NG2 binding peptide exhibits significant homing ability in wild-type tumor-bearing mice, but has no localization effect in NG2 knockout mice. Due to the tissue specificity of NG2 expression, NG2 binding peptide can be used in scenarios such as tumor targeted therapy, drug delivery, and molecular imaging diagnosis.
Others  
Cancer  
/
HY-15233G Letermovir (GMP)
Letermovir (GMP) is the GMP grade of Letermovir (HY-15233). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Letermovir (GMP) is an orally active CMV inhibitor. Letermovir (GMP) targets the CMV terminase complex rather than CMV DNA polymerase and exerts its antiviral activity. Letermovir (GMP) can be used in the study of CMV infection.
CMV  
Cytomegalovirus Infection  
/
HY-10321G PD173074 (GMP)
PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active FGFR inhibitor that targets the transphosphorylation of FGFR1 and FGFR2 and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses FGF-2-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer.
FGFR   TGF-beta/Smad  
Small Cell Lung Cancer  
/
HY-19980G Eprenetapopt (GMP)
Eprenetapopt (GMP) (APR-246(GMP)) is Eprenetapopt (HY-19980) in GMP grade. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance.
MDM-2/p53   Ferroptosis   Autophagy   Apoptosis  
Non-Small Cell Lung Cancer  
/
HY-I0626S Cytosine-13C2,15N3
Cytosine-13C2,15N3 is the 13C-labeled and 15N-labeled Cytosine. Cytosine is one of the four main bases found in DNA and RNA. Cytosine modifications exhibit circadian oscillations that are involved in epigenetic diversity and aging.
Endogenous Metabolite  
/
HY-12238G IWR-1 (GMP)
IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis.
Organoid   Wnt  
Inflammation or Immune System Disease  
/
HY-117275S1 Meclofenamic acid-13C6
Meclofenamic acid-13C6 is the 13C6 labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker.
Isotope-Labeled Compounds   Gap Junction Protein   Endogenous Metabolite  
Inflammation or Immune System Disease  
/
HY-117275R Meclofenamic acid (Standard)
Meclofenamic acid (Standard) is the analytical standard of Meclofenamic acid. This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
Reference Standards   Fat Mass and Obesity-associated Protein (FTO)   Potassium Channel   Gap Junction Protein   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N16733 Deacetyltanghinin
Deacetyltanghinin is a selective inhibitor targeting Na+/K+ ATPase, acting through non-covalent binding but is highly cardiotoxic. Deacetyltanghinin inhibits Na+/K+ ATPase activity, induces cancer cell apoptosis (involving caspase pathway activation), and at the same time affect the TXA2-PGI2 balance in the rabbit heart. Deacetyltanghinin has significant anti-cancer activity and is mainly used in the research field of targeted therapy of malignant tumors such as breast cancer and lung cancer. At the same time, attention should be paid to the regulation of its cardiotoxicity.
Na+/K+ ATPase   Prostaglandin Receptor   Caspase   Apoptosis  
Lung Cancer   Breast Cancer  
/
HY-P992519 PF-06940434
PF-06940434 (ADWA-11) is a monoclonal antibody targeting integrin αvβ8. PF-06940434 inhibits αvβ8-mediated TGF-β activation. PF-06940434 increases the accumulation of tumor-infiltrating CD8+ T cells and upregulates the expression of granzyme B and TNF-γ. PF-06940434 blocks the inhibitory effect of CD4+CD25+ T cells on the cytotoxic activity of tumor CD8+ T cells. PF-06940434 enhances the anti-tumor efficacy of combination therapies with other immunomodulators or radiotherapy and induces long-term anti-tumor immunity. PF-06940434 can be used in the research of squamous cell carcinoma, breast cancer, colon cancer, and prostate adenocarcinoma.
Integrin   TNF Receptor   TGF-β Receptor  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Squamous Cell Carcinoma  
/
HY-13689G Go 6983 (GMP)
Go 6983 GMP is Go 6983 (HY-13689) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Go 6983 is a dual inhibitor targeting Suv39h1/2 (KMT1A/KMT1B) and PKC, as well as a transcriptional activator capable of inducing DNA hypomethylation. Go 6983 stimulates the transcription of Prdm14 by reducing Suv39h1/2 protein levels, decreasing histone modifications in the Prdm14 promoter region, and increasing the recruitment of RNA polymerase II. Go 6983 induces genome-wide DNA hypomethylation by inhibiting de novo methyltransferase expression and increasing Tet1/Tet2 levels, thereby promoting self-renewal and pluripotency maintenance of stem cells. Meanwhile, Go 6983 can block PKC-mediated signaling pathways to reduce the expression of EMT-related genes and eliminate the upregulation of antioxidant genes downstream of NRF2. Go 6983 is mainly used in mechanism studies related to myocardial ischemia/reperfusion injury.
PKC   Histone Methyltransferase   DNA Methyltransferase   DNA/RNA Synthesis  
Ischemia-Reperfusion Injury  
/
HY-D2620 CAR-2
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC50 of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models.
Photosensitizer   Reactive Oxygen Species (ROS)   Ferroptosis  
/
HY-112582S N1-Methylpseudouridine-d3
N1-Methylpseudouridine-d3 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.
Nucleoside Antimetabolite/Analog  
Cancer  
/
HY-113011R Maltotriose (Standard)
Maltotriose (Standard) is the analytical standard of Maltotriose (HY-13011). This product is intended for research and analytical applications. Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
Reference Standards   Endogenous Metabolite  
/
HY-N4031 Humantenine
Humantenine is a highly toxic indole alkaloid from Gelsemium elegans (Gardn. & Champ.) Benth. that binds to RNA m6A modification regulatory proteins (ALKBH5, METTL). Humantenine stably binds via hydrogen bonding and hydrophobic interactions and disrupts the m6A methylation level of target genes, thereby impairing the expression of intestinal epithelial cell tight junction and cytoskeleton-related genes, causing intestinal barrier dysfunction and significant intestinal cytotoxicity. The intraperitoneal injection LD50 values of Humantenine are <1 mg/kg in mice, 1.2 mg/kg in male rats and 1.5 mg/kg in female rats, respectively. Species differences exist in the metabolism of Humantenine in human, porcine, goat and rat liver microsomes, and demethylation, dehydrogenation and oxidation occur in liver microsomes.
Anaplastic lymphoma kinase (ALK)   METTL3  
Digestive System Disease  
/
HY-B1320R Meclofenamic acid sodium (Standard)
Meclofenamic acid (sodium) (Standard) is the analytical standard of Meclofenamic acid (sodium). This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) sodium is a non-steroidal anti-inflammatory agent (NSAID). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat - and obesity-related enzyme (FTO). Meclofenamic acid sodium has anti-inflammatory and antitumor activities.
Reference Standards   Gap Junction Protein   Endogenous Metabolite   Fat Mass and Obesity-associated Protein (FTO)  
Cancer   Inflammation or Immune System Disease  
/
HY-W013741 CME-carbodiimide
CME-carbodiimide is a nucleic acid modification reagent. CME-carbodiimide reacts specifically with uracil and guanine residues of RNA, as well as guanine and thymine residues of denatured DNA; it does not react with native DNA. Modification of DNA by CME-carbodiimide inhibits phosphodiester bond cleavage or DNA hydrolysis mediated by pancreatic ribonuclease, snake venom phosphodiesterase and deoxyribonuclease.
Biochemical Assay Reagents   DNA Alkylator/Crosslinker   DNA/RNA Synthesis  
/
HY-P11286 A7RC
A7RC is a multifunctional peptide used in tumor-targeted therapy, with Cysteine added to the C-terminal of the A7R peptide (sequence: ATWLPPR). A7R (HY-P1663) is a ligand of the NRP-1 receptor, regulating intracellular signal transduction related to tumor vascularization and tumor growth.
Complement System  
Cancer  
/
HY-19528S2 SAH-13C10
SAH-13C10 is the 13C labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-14280S Entacapone-d10
Entacapone-d10 is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 μM). Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders.
COMT  
Neurological, Eye or Ear Disease  
/
HY-P991689 Girancitug
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-P11280A PRAME peptide (425-433) acetate
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma.
Melanocortin Receptor  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Lung Squamous Cell Carcinoma   Squamous Cell Carcinoma  
/
HY-P4091 LSD
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics.
Biochemical Assay Reagents  
Cancer  
/
HY-P991294 MGTA-117 Antibody
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy.

Species: Human

ADC Antibodies  
Cancer  
/
HY-I0626S1 Cytosine-13C,15N2
Cytosine-13C,15N2 is the 13C and 15N labeled Cytosine. Cytosine is one of the four main bases found in DNA and RNA. Cytosine modifications exhibit circadian oscillations that are involved in epigenetic diversity and aging.
Endogenous Metabolite  
/
HY-P5931 Spinoxin
Spinoxin isolated from the venom of scorpion Heterometrus spinifer, is a 34-residue peptide neurotoxin cross-linked by four disulfide bridges. Spinoxin is a potent inhibitor of Kv1.3 potassium channel (IC50 = 63 nM), considering to be valid molecular targets in the diagnostics and therapy of various autoimmune disorders and cancers.
Potassium Channel  
Cancer   Inflammation or Immune System Disease  
/
HY-N0086S2 N6-Methyladenosine-13C4
N6-Methyladenosine-13C4 (6-Methyladenosine-13C4; N-Methyladenosine-13C4) is 13C-labeled N6-Methyladenosine (HY-N0086). N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
Isotope-Labeled Compounds   Influenza Virus   Endogenous Metabolite  
Infection  
/
HY-P990716 Sabestomig
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma.

Species: Human

PD-1/PD-L1   Tim3  
Inflammation or Immune System Disease  
/
HY-P99382A Vopratelimab (Mouse IgG2a)
Vopratelimab (Mouse IgG2a) is a agonist monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy.

Species: Human

Others  
Cancer  
/
HY-15764G A 419259 (GMP)
A 419259 GMP is the GMP grade A 419259 (HY-15764), inducing cell apoptosis. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. A 419259 (RK-20449) is a broad-spectrum pyrrole-pyrimidine inhibitor targeting Src, Lck, and Lyn with IC50s of 9 nM, <3 nM, and <3 nM, respectively.
Src   Apoptosis  
Cancer  
/
HY-113081S 1-Methyladenosine-d3
1-Methyl Adenosine-d3 is the deuterium labeled 1-Methyladenosine. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
Isotope-Labeled Compounds   Endogenous Metabolite   PPAR   Hedgehog  
/
HY-113061R Pseudouridine (Standard)
Pseudouridine (Standard) is the analytical standard of Pseudouridine. This product is intended for research and analytical applications. Pseudouridine is an isomer of the nucleoside uridine, and the most abundant modified nucleoside in non-coding RNAs. Pseudouridine in rRNA and tRNA can fine-tune and stabilize the regional structure and help maintain their functions in mRNA decoding, ribosome assembly, processing and translation[4].
Reference Standards   Endogenous Metabolite   Nucleoside Antimetabolite/Analog   DNA/RNA Synthesis  
/
HY-113081AS 1-Methyladenosine-d3 hydrochloride
1-Methyladenosine-d3 hydrochloride is the hydrochloride salt form of deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
Isotope-Labeled Compounds   Endogenous Metabolite   PPAR   Hedgehog  
Cancer  
/
HY-113081R 1-Methyladenosine (Standard)
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis. In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells.
Reference Standards   Endogenous Metabolite   PPAR   Hedgehog  
Cancer  
/
HY-P2213A GPLGIAGQ TFA
GPLGIAGQ TFA, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ TFA can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT).
MMP   Apoptosis  
Cancer  
/
HY-W008091S 5-Methylcytosine-d4
5-Methylcytosine-d4 is the deuterium labeled 5-Methylcytosine (HY-W008091). 5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma.
DNA/RNA Synthesis   Endogenous Metabolite   Isotope-Labeled Compounds  
/
HY-113081S1 1-Methyladenosine-d3 hydriodide
1-Methyladenosine-d3 hydriodide is the deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
Isotope-Labeled Compounds   Endogenous Metabolite   PPAR   Hedgehog  
Cancer  
/
HY-W008951 Ethylenediaminetetra(methylenephosphonic acid)
Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers.
Radionuclide-Drug Conjugates (RDCs)  
Pain   Multiple Myeloma  
/
HY-168610 YTH-IN-1
YTH-IN-1 (compound N-7) is a pan-YTH domain inhibitor with the IC50 values of 39 μM, 34 μM, 35 μM, 48 μM and 30 μM for human YTHYTHDF1, YTHYTHDF2, YTHYTHDF3, YTHYTHDC1, and YTHYTHDC2, respectively.
Epigenetic Reader Domain   YTHDF  
Cancer  
/
HY-176848 SKLB-Y13
SKLB-Y13 is a selective YTHDF1 inhibitor with an IC50 of 0.76 μM and a KD of 5.097 μM. SKLB-Y13 binds to the Tyr397 and Trp470 residues in the m6A-binding pocket of YTHDF1, disrupting the interaction between YTHDF1 and m6A-modified mRNA. SKLB-Y13 inhibits cancer cell proliferation and promotes apoptosis. SKLB-Y13 is applicable to breast cancer-related research.
YTHDF   Apoptosis   MMP   Caspase  
Breast Cancer  
/
HY-174982 YTHDF2 ligand-1
YTHDF2 ligand-1 (Compound 23) is a competitive, selective, and high-affinity YTHDF2 ligand with an IC50 of 11 μM and a Kd of 1.3 μM. YTHDF2 ligand-1 competes with m6A-RNA for binding to YTHDF2. YTHDF2 ligand-1 is applicable for cancer research.
YTHDF  
Cancer  
/
HY-P2213 GPLGIAGQ
GPLGIAGQ, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT).
MMP   Apoptosis  
Pancreatic Cancer   Pain   Digestive System Inflammation  
/
HY-I0626S2 Cytosine-d2
Cytosine-d2 is the deuterium labeled Cytosine. Cytosine is one of the four main bases found in DNA and RNA. Cytosine modifications exhibit circadian oscillations that are involved in epigenetic diversity and aging.
Endogenous Metabolite  
/
HY-169396 TAE648
TAE648 is a target protein ligand of PROTAC SK-3-91 (HY-137341) (Ligand for Target Protein for PROTAC). TAE648 can be used for synthesis PROTAC. TAE648 decreases monolayer-cultured SKOV3ip1 cell viability.
Ligands for Target Protein for PROTAC   Microtubule/Tubulin   YTHDF   CDK   Btk   FLT3   Aurora Kinase   Tyrosinase   ULK   Itk  
Cancer  
/
HY-19528R SAH (Standard)
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM.
Reference Standards   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-173008 YTHDF2-IN-1
YTHDF2-IN-1 (Compound CK-75) is a selective YTHDF2 inhibitor (Kd = 26.2 μM). YTHDF2-IN-1 binds to a small hydrophobic pocket on the YTH domain of YTHDF2, disrupting the interaction between YTHDF2 and m6A-modified RNA. YTHDF2-IN-1 induces cell cycle arrest and Apoptosis. YTHDF2-IN-1 is applicable to research on chronic myeloid leukemia, colon cancer and choriocarcinoma.
Apoptosis   YTHDF  
Colorectal Cancer   Leukemia/Lymphoma/Myeloma  
/
HY-N0086S N6-Methyladenosine-d3
N6-Methyladenosine-d3 (6-Methyladenosine-d3; N-Methyladenosine-d3) is a deuterium labeled N6-Methyladenosine (HY-N0086). N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities.
Isotope-Labeled Compounds   Endogenous Metabolite   Influenza Virus  
Infection  
/
HY-137341 SK-3-91
SK-3-91 is a multi-kinase PROTAC degrader that induces the degradation of the maximum number of unique kinases (over 125 distinct kinases) simultaneously. SK-3-91 induces protein degradation via the ubiquitin biotinylation (E-STUB) pathway, such as inducing the degradation of YTHDF2. SK-3-91 also inhibits cell proliferation and induces cell morphological changes. SK-3-91 can be used in research related to acute lymphoblastic leukemia, multiple myeloma, neuroblastoma, ovarian cancer, mantle cell lymphoma, and gastric cancer.
PROTACs   YTHDF  
Gastric Cancer   Ovarian Cancer   Neuroblastoma   Acute Lymphoblastic Leukemia   Multiple Myeloma  
/
HY-P990059 Puxitatug
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer.

Species: Human

ADC Antibodies   CD276/B7-H3  
Cancer  
/
HY-19528S SAH-d4
SAH-d4 is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-145746 Sulfo-Cy5 azide
Sulfo-Cy5 azide is a near-infrared fluorescent probe with favorable click chemistry reactivity. Sulfo-Cy5 azide enables fluorescence imaging, tissue and cellular visualization of PD-L1 in tumors, and site-specific modification of anti-PD-L1 antibodies. Sulfo-Cy5 azide has been employed for RNA labeling and imaging. Sulfo-Cy5 azide can be conjugated to targeting agents for fluorescence imaging in atherosclerosis and breast cancer models (Ex/Em = 645/670 nm).
Fluorescent Dye   PD-1/PD-L1  
Breast Cancer   Atherosclerosis and Inflammation  
/
HY-P5911 GluN1(359-378)
GluN1 (359-378) is an anti-N-methyl-D-aspartate receptor (NMDAR) peptide. GluN1 (359-378) can cross the blood-brain barrier. GluN1 (359-378) can be used to study anti-NMDAR encephalitis therapy targeting the immune system.
iGluR  
Inflammation or Immune System Disease  
/
HY-W074785 Carboxyl diazirine alkyne
Carboxyl diazirine alkyne is a protein cross-linking compound. Carboxyl diazirine alkyne plays a crucial role in the research on the inhibition and labeling of FTO protein by fluorescein derivatives.
Biochemical Assay Reagents  
/
HY-P702576 YTHDF2 Protein, Human (His)
YTHDF2 Protein, Human (His) is the recombinant human-derived YTHDF2, expressed by E. coli , with C-6*His labeled tag. ,

Species: Human; Source: E. coli

/
HY-P705543 ALKBH5 Protein, Human (His)

Species: Human; Source: E. coli

Enzymes & Regulators

/
HY-P701888 FTO Protein, Human (His)
FTO protein is an RNA demethylase that regulates fat mass, lipogenesis, and energy homeostasis by targeting N(6)-methyladenosine in mRNA. It also demethylates m6A in U6 snRNA and m6A(m) in 5'-cap, affecting mRNA stability. FTO Protein, Human (His) is the recombinant human-derived FTO protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Oxidoreductases (EC 1)

/
HY-P703326 PUS7 Protein, Human (sf9, His, Strep)
PUS7 Protein, Human (sf9, His, Strep) is the recombinant human-derived PUS7, expressed by sf9 insect cells , with Strep, His labeled tag. ,

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Isomerases (EC 5)

/
HY-P703633 METTL14-METTL3 Protein, Human (sf9, His, Strep)
METTL3 and METTL14 are important players in RNA methylation specifically involved in N6-methyladenosine (m6A) modification. METTL3 and METTL14 have shown associations with certain cancers and neurological disorders. METTL14-METTL3 Protein, Human (sf9, His, Strep) is expressed by Sf9 insect cells and carries Strep and His tags.

Species: Human; Source: Sf9 insect cells

/
HY-P702912 METTL3 Protein, Human (sf9, FLAG)
METTL3 Protein, Human (sf9, FLAG) is the recombinant human-derived METTL3, expressed by Sf9 insect cells , with N-Flag labeled tag. ,

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Transferases (EC 2)

/
HY-P703029 METTL3 Protein, Human (sf9, GST)
METTL3 Protein, Human (sf9, GST) is the recombinant human-derived METTL3, expressed by Sf9 insect cells , with GST labeled tag. ,

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Transferases (EC 2)

/
HY-P703032 TRIB1 Protein, Human (sf9, GST)
TRIB1 Protein, Human (sf9, GST) is the recombinant human-derived TRIB1, expressed by Sf9 insect cells , with GST labeled tag. ,

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Isomerases (EC 5)

/
HY-P705470 METTL3 Protein, Human (His)

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P83693 ALKBH5 Antibody (YA3429)
ALKBH5 Antibody (YA3429) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ALKBH5.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80680 FTO Antibody (YA424)
FTO Antibody (YA424) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FTO.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81684 YTHDF1 Antibody (YA1429)
YTHDF1 Antibody (YA1429) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to YTHDF1.

Host: Rabbit; Reactivity: Human, Hamster

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86454 YTHDF2 Antibody (YA6146)
YTHDF2 Antibody (YA6146) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to YTHDF2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86598 METTL3 Antibody (YA6290)
METTL3 Antibody (YA6290) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to METTL3.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811330 YTHDF3 Antibody
YTHDF3 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to YTHDF3.

Host: Rabbit; Reactivity: Human, Mouse

Polyclonal Antibodies Primary Antibodies

/
HY-P86545 YTHDF1 Antibody (YA6237)
YTHDF1 Antibody (YA6237) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to YTHDF1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80680A FTO Antibody (YA424)(PBS only)
FTO Antibody (YA424) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FTO.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810843 ADAR2 Antibody
ADAR2 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to ADAR2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P81684A YTHDF1 Antibody (YA1429)(PBS only)
YTHDF1 Antibody (YA1429) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to YTHDF1.

Host: Rabbit; Reactivity: Human, Hamster

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82541 TRUB2 Antibody (YA2286)
TRUB2 Antibody (YA2286) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TRUB2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82541A TRUB2 Antibody (YA2286)(PBS only)
TRUB2 Antibody (YA2286) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TRUB2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86495 FTO Antibody (YA6187)
FTO Antibody (YA6187) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to FTO.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810920 MRPL12 Antibody
MRPL12 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to MRPL12.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-KE7066 FnCas12a

FnCas12a(Cpf1), is an RNA-guided, DNA-editable recombinant endonuclease that can be used for gene editing and detection.

Molecular Biology Restriction Endonuclease

/

References

[1]. Xiong X, et al. Epitranscriptomics: toward a better understanding of RNA modifications. Genomics Proteomics Bioinformatics. 2017;15(3):147-153.  [Content Brief]

[2]. Yi C, et al. RNA modifications and epitranscriptomics. Genomics Proteomics Bioinformatics. 2023;21(4):675-677.  

[3]. Pagiatakis C, et al. The RNA methylome blackboard: METTL3 and FTO, epigenetic writers and erasers regulating cardiac homeostasis through epitranscriptome modification. Circulation. 2019;139(5):546-548.  [Content Brief]

[4]. Petri BJ, et al. m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer. J Mol Endocrinol. 2023;70(1):e220110.  

[5]. Rauch S, et al. Targeted m6A reader proteins to study epitranscriptomic regulation of single RNAs. J Am Chem Soc. 2018;140(38):11974-11981.  [Content Brief]

[6]. Akçaöz A, et al. Epitranscriptomics changes the play: m6A RNA modifications in apoptosis. Adv Exp Med Biol. 2022  

[7]. Qu Z, et al. Epitranscriptomic orchestrations: unveiling the regulatory paradigm of m6A, A-to-I editing, and m5C in breast cancer via long noncoding RNAs and microRNAs. Cell Biochem Funct. 2024;42:e3996.  

[8]. Lin LC, et al. m6A epitranscriptomic modification in diabetic microvascular complications. Trends Pharmacol Sci. 2023;44(12):983-997.  [Content Brief]

[9]. Zhang YS, et al. m6A epitranscriptomic modification of inflammation in cardiovascular disease. Int Immunopharmacol. 2024;134:112222.  

[10]. Stopa V, et al. Epitranscriptomics in atherosclerosis: unraveling RNA modifications, editing and splicing and their implications in vascular disease. Vasc Pharmacol. 2025:107496.  

[11]. Esteller M. Targeting RNA modifications in leukaemia: epitranscriptomic drugs are the new kids on the block. Br J Haematol. 2024;206(4):785-787.  

[12]. Maździarz M, et al. Epitranscriptomic signatures of m5C, m6A, and pseudouridine in COVID-19 reveal host RNA modifications involved in viral pathogenesis. Microbiol Spectr. 2026;14.  

Keywords

RNA modification | epitranscriptomics | m6A | m5C | pseudouridine | RNA editing | METTL3 | FTO | ALKBH5 | YTHDF | targeted therapy